Common Contracts
4 similar Underwriting Agreement contracts by Bone Biologics Corp, Armlogi Holding Corp., Lixte Biotechnology Holdings, Inc.
ARMLOGI HOLDING CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • May 15th, 2024 • Armlogi Holding Corp. • Public warehousing & storage • New York
BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT 3,777,778 Units Consisting of 3,777,778 Shares of Common Stock, And 3,777,778 Series A Warrants to Purchase 3,777,778 Shares of Common Stock And 3,777,778 Series B Warrants to Purchase 3,777,778 Shares...Underwriting Agreement • October 11th, 2022 • Bone Biologics Corp • Orthopedic, prosthetic & surgical appliances & supplies • New York
BONE BIOLOGICS CORPORATION, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”), an aggregate of 3,777,778 Units (the “Firm Units”), each Firm Unit consisting of: (i) one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”); (ii) one Series A warrant to purchase one share of Common Stock (the “Series A Warrants” and each a “Series A Warrant”); (iii) one Series B warrant to purchase one share of Common Stock (the “Series B Warrants” and each a “Series B Warrant”); and (iv) one Series C warrant to purchase one share of Common Stock (the “Series C Warrants” and each a “Series C Warrant” and together with Series A Warrants and Series B Warrants, the Purchase Warrants). The 3,777,778 shares of Common Stock referred
BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT [ ]Units Consisting of [ ] Shares of Common Stock, AndUnderwriting Agreement • September 23rd, 2022 • Bone Biologics Corp • Orthopedic, prosthetic & surgical appliances & supplies • New York
BONE BIOLOGICS CORPORATION, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”), an aggregate of [ ] Units (the “Firm Units”), each Firm Unit consisting of: (i) one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”); (ii) one Series A warrant to purchase one share of Common Stock (the “Series A Warrants” and each a “Series A Warrant”); (iii) one Series B warrant to purchase one share of Common Stock (the “Series B Warrants” and each a “Series B Warrant”); and (iv) one Series C warrant to purchase one share of Common Stock (the “Series C Warrants” and each a “Series C Warrant” and together with Series A Warrants and Series B Warrants, the Purchase Warrants). The [ ] shares of Common Stock referred to in this S
LIXTE BIOTECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT [*] Shares of Common StockUnderwriting Agreement • October 13th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WestPark Capital Inc. is acting as representative (the “Representative”), an aggregate of [*] authorized but unissued shares of common stock, par value $0.0001 per share, (the “Common Stock”) of the Company (the “Firm Shares”). The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, up to an additional [*] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares” or the “Securities”.
